The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Inflammation Biomarkers Program, 2018Using Changes in Immune Cells to Diagnose or Track Parkinson's Disease
Study Rationale:
There are currently no Parkinson's disease (PD) biomarkers -- objective measures of disease -- in clinical use, but several blood biomarkers are being developed. Some of these... -
Research Grant, 2018A Global Search for People with a Rare, Inherited Form of Parkinson's Disease
Study Rationale:
Mutations, or changes, in the genes PRKN and PINK1 cause inherited Parkinson's disease (PD) that starts at an early age. This type of Parkinson's accounts for roughly 13 percent of... -
Target Advancement Program, 2018Causes, Mechanism and Consequences of an Energy Crisis in Striatal Nerve Endings
Study Rationale:
Two proteins, PINK1 and parkin, prevent cell death by breaking down damaged mitochondria, cell's energy generators. Mutations in the PINK1/PRKN genes - genetic changes that render... -
Target Advancement Program, 2018Neuroprotective Effects of NFE2L1 in Parkinson's Models
Study Rationale:
NFE2L1 is a protein that controls the expression of genes involved in the differentiation and survival of dopamine neurons. NFE2L1 levels are reduced in dopamine neurons in the brains... -
Therapeutic Pipeline Program, 2018Development of ALK4290 as a Novel Parkinson's Therapeutic
Study Rationale:
There is clear evidence that the immune system plays an important role in the development and progression of Parkinson's disease. Novel therapies targeting the recruitment of immune... -
Target Advancement Program, 2018Searching for Cellular Changes Associated with PINK1 and PRKN Mutations
Study Rationale:
PINK1 and parkin are two proteins that work together to keep cells healthy by ridding them of damaged mitochondria, cells' powerhouses. Mutations (changes) in the PINK1 and PRKN genes...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.